Dadadak Healthcare, a non-face-to-face pediatric innovative medical device and medical service company, announced on the 20th that it has secured a Seedbridge investment from MY Social Company (MYSC). This investment was executed through the Korea Impact Scale-Up Investment Fund, managed by MYSC and The Wells Investment, with participation from several investors, including BTB Ventures and Seoul National University Technology Holdings.
Dadadak Healthcare plans to use this investment to advance its medical devices, refine its AI-assisted diagnostic system, and expand its non-face-to-face pediatrics operation model. The company plans to expand its services by developing medical devices capable of measuring key biometric data such as body temperature, respiratory sounds, and ear and throat images at home, as well as a sophisticated remote medical treatment system based on these devices. This will focus on expanding services to areas with limited access to healthcare and to dual-income and medically vulnerable families.
Dadadak Healthcare differentiates itself from existing telemedicine services by establishing a "measurement-based, non-face-to-face pediatrics" model. It combines proprietary medical devices with AI-assisted diagnostic technology to enable hospital-quality pediatric care at home.
The company's competitive edge lies in its vertical structure, which integrates medical devices, AI, hospital operations, and data. It boasts a team equipped with medical device development and licensing capabilities, AI and data technology, and experience in pediatric hospital operations. The clinical data accumulated at its directly operated hospitals will be utilized for future AI advancements and franchise expansion.
Dadadak Healthcare is currently piloting a non-face-to-face pediatrics model in the Busan and Gyeongnam regions. It plans to expand nationwide and expand into a multi-layered revenue model, including pediatrics franchises, medical device sales and rentals, and subscription-based healthcare services. In the long term, it is also considering collaborations with insurance and pharmaceutical companies and overseas expansion.
An official from MYSC, which executed the investment, evaluated Dadadak Healthcare as “a company with a unique position as a measurement-based, non-face-to-face pediatric clinic and high technological and institutional barriers to entry,” and stated that it has high potential to simultaneously improve medical accessibility and medical system efficiency.
Shin Gwang-il, CEO of Dadadak Healthcare, said, “Through this investment, we will strengthen the accuracy and reliability of non-face-to-face pediatric care and build a pediatric healthcare ecosystem where all children, regardless of region, income, or environment, can receive timely treatment.”
The company plans to use this investment as an opportunity to expand its model of providing the same level of pediatric care to rural, fishing, and medically underserved areas, while also exploring global expansion.
You must be logged in to post a comment.